Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing

Lindsay J Dick, Andrew Gray, Asha Ram, Aileen Hume, Caroline Parris, Philip J Hogg, Moira A Elliott, Steven J Ford, Gavin W Halbert

Research output: Contribution to journalArticle

Abstract

Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.
LanguageEnglish
Pages1664–1669
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Volume65
Issue number11
Early online date18 Sep 2013
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Arsenicals
Infertility
Amino Acids
Neoplasms
Poisons
Therapeutics
Anti-Bacterial Agents
Growth
Pharmaceutical Preparations
phenylarsonous acid

Keywords

  • arsenical
  • British anti-Lewisite
  • deactivation
  • sterility
  • DMP

Cite this

@article{1bd1eb0c721a43a18890f3566bc22533,
title = "Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing",
abstract = "Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.",
keywords = "arsenical, British anti-Lewisite, deactivation, sterility, DMP",
author = "Dick, {Lindsay J} and Andrew Gray and Asha Ram and Aileen Hume and Caroline Parris and Hogg, {Philip J} and Elliott, {Moira A} and Ford, {Steven J} and Halbert, {Gavin W}",
note = "{\circledC} 2013 Royal Pharmaceutical Society.",
year = "2013",
month = "11",
doi = "10.1111/jphp.12143",
language = "English",
volume = "65",
pages = "1664–1669",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
number = "11",

}

TY - JOUR

T1 - Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing

AU - Dick, Lindsay J

AU - Gray, Andrew

AU - Ram, Asha

AU - Hume, Aileen

AU - Parris, Caroline

AU - Hogg, Philip J

AU - Elliott, Moira A

AU - Ford, Steven J

AU - Halbert, Gavin W

N1 - © 2013 Royal Pharmaceutical Society.

PY - 2013/11

Y1 - 2013/11

N2 - Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.

AB - Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.

KW - arsenical

KW - British anti-Lewisite

KW - deactivation

KW - sterility

KW - DMP

UR - http://www.scopus.com/inward/record.url?scp=84886102014&partnerID=8YFLogxK

U2 - 10.1111/jphp.12143

DO - 10.1111/jphp.12143

M3 - Article

VL - 65

SP - 1664

EP - 1669

JO - Journal of Pharmacy and Pharmacology

T2 - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 11

ER -